Background: We investigated the maximum tolerated dose (MTD) of combination therapy with docetaxel, cisplatin, and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer (HNC). /day, every 3 weeks), 2 DLTs were seen. Six achieved a complete response and 22 a partial response, giving a response rate of 70%.
introduction
Head and neck cancers (HNCs) are the sixth most common cancer in the world, and $500 000 new cases are projected annually [1] . An estimated 60% of these patients will present with locally advanced disease (stage III/IV).
Platinum-based chemotherapy is widely used for recurrent/ metastatic HNC. The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) (TPF) has been considered the standard regimen for induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [2, 3] . Nevertheless, this combination is stressful to patients, and the continuous infusion of 5-FU in this combination reduces quality of life, owing not only to toxicity but also to inconvenience and catheter-related complications. Other options with improved safety profiles and greater convenience are thus highly desirable.
In response to this need, one growing trend has been the substitution of conventional 5-FU with the oral prodrug of 5-FU. S-1 is a novel oral fluoropyrimidine derivative, which consists of tegafur, gimeracil (5-chloro-2, 4-dihydrogenase; CDHP), and potassium oxonate (Oxo) at a molar ration of 1 : 0.4 : 1 [4] . Tegafur is a prodrug of 5-FU. CDHP augments the activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase. Oxo reduces gastrointestinal (GI) toxicity by inhibiting orotate phosphoribosyl transferase and 5-FU phosphorylation in intestinal mucosa [5] .
S-1 has shown activity against HNC, producing a response rate of 34% [6] . A combination of cisplatin and S-1 shows promising efficacy (response rate: 67.6%) with acceptable toxicity for locally advanced HNC [7] . Furthermore, a combination of docetaxel and S-1 has demonstrated promising efficacy with acceptable toxicity for many cancers [8] [9] [10] [11] .
Based on these promising results, we speculated that replacing 5-FU with S-1 in combination with docetaxel and cisplatin would be a reasonable alternative to continuous infusion of 5-FU. To our knowledge, however, combination therapy with docetaxel, cisplatin, and S-1 (TPS) in the treatment of HNC has not been investigated.
Here, we conducted a phase I study of a combination therapy with TPS in patients with locally advanced or recurrent/ metastatic HNC.
patients and methods

eligibility criteria
All patients had a histologically or cytologically confirmed diagnosis of HNC with recurrent/metastatic or unresectable locally advanced disease. Eligibility also required an Eastern Cooperative Oncology Group performance status of zero or one, age 20-75 years, and adequate organ function. Written informed consent was required from all patients before the start of study therapy.
Patients were excluded for any of the following conditions: history of prior chemotherapy; concurrent active malignancy except excised intramucosal gastric or esophageal cancer, which could be removed by endoscopic mucosal resection; pharyngeal fistula; active bleeding from the GI tract; active infection; serious medical problem that might interfere with the achievement of study objectives; pregnancy or lactation; or expected survival of <3 months.
The study was approved by the Institutional Review Board at the National Cancer Center.
study design
The study was conducted as an open-label, single arm, phase I, singleinstitution dose-escalation study aimed at testing the safety of combination therapy with TPS in patients with locally advanced or recurrent/metastatic HNC. A total of six dose combinations were planned (Table 1) .
Toxic effects were evaluated according to National Cancer Institute-Common Toxicity Criteria for Adverse Events version 2.0. A minimum of three assessable patients was treated at each dose level. If one of the three patients at a given dose level experienced a dose-limiting toxicity (DLT), three additional patients were accrued at the same dose level. The maximum tolerated dose (MTD) was defined as the dose at which two or more patients of six experienced a DLT. After the MTD was determined, three more patients were treated at the next lower dose level. If no or only one of the six patients experienced a DLT, an additional six patients were accrued at the same dose level to determine the recommended dose (RD). No intra-patient dose escalation was allowed.
DLT was defined as any of the following adverse events occurring within 30 days after completion of the first cycle of TPS: (i) febrile neutropenia lasting >4 days; (ii) grade 4 thrombocytopenia (<10 000/mm 3 Table 1 . At dose levels 1-4, treatment was repeated every 4 weeks, with a maximum of six cycles allowed until unacceptable toxicity, patient refusal or disease progression was observed. At dose levels 5 and 6, the subject had to have locally advanced HNC and to have received TPS every 3 weeks with a maximum of three cycles allowed. Patients with locally advanced HNC who recorded a response after completion of three cycles of TPS were able to receive definitive treatment, including concurrent chemoradiotherapy.
treatment evaluation and dose modifications
Baseline evaluation consisted of history, physical examination, radiographic imaging, routine laboratory studies, and electrocardiogram. Safety assessments were repeated weekly after the start of chemotherapy.
Doses were modified in case of severe hematological or nonhematological toxic effects. Since patients received three chemotherapeutic agents, dose adjustment was carried out for each individual agent based on its estimated causal relationship to the toxicity; if multiple agents were felt to be causing the toxicity, dose reduction was carried for multiple agents according to the RD reduction schedule below. If multiple toxic effects occurred during a treatment cycle, the toxicity with the highest grade was used as the parameter for dose adjustment.
Grade 4 hematological toxic effects or grade 3 infection required a dose reduction of all three drugs. Grade 3 diarrhea, mucositis, or skin reaction required a reduction in S-1 dose. Grade 2 neurotoxicity required a reduction in cisplatin dose. Grade 3 neurotoxicity required the discontinuation of cisplatin. Creatinine clearance (CCr) was calculated at the beginning of each cycle according to the Cockcroft-Gault formula. CCr values >60 ml/min required no dose modification; those from 50 to <60 ml/ min required a reduction in both S-1 and cisplatin by one dose level; those from 40 to <50 ml/min required a reduction of both S-1 and cisplatin by two dose levels; and those <40 ml/min required the cessation of both S-1 and cisplatin. Patients were removed from treatment if more than two dose reductions were required or if there was a treatment delay of >21 days due to toxicity.
Tumors responses were evaluated according to RECIST. The primary end point in this study was the MTD and RD of this regimen. Secondary end points included the safety and tolerability of this combination and relative dose intensity and efficacy, including response rate, progression-free survival (PFS), and overall survival (OS).
Relative dose intensity was calculated as the ratio of the actual to planned dose intensity in milligrams per square meter per week. The survival curve was estimated using the Kaplan-Meier method. Safety and efficacy analyses were both conducted on an intention-to-treat (ITT) population, defined as all patients enrolled in the study who received at least one dose of chemotherapy. A subject's PFS was defined as the time from the date of the first administration of chemotherapy to the first documentation of disease progression, subsequent therapy, or death. OS was determined from the date of the first administration of chemotherapy to the date of death or the last confirmation of survival. Statistical data were obtained using the SPSS software package (SPSS 11.0 Inc., Chicago, IL). Table 2 .
Twenty-nine cases were locally advanced cancer and 11 were recurrent/metastatic cancer.
treatment administration
A total of 116 cycles was administered (median = 3, range 1-6) over six dose levels. Twenty cycles required dose reduction, while six required a delay of >7 days due to toxicity. Six patients discontinued treatment due to disease progression and two due to treatment-related toxicity, while two other patients refused further treatment due to fatigue. Three of 11 patients with recurrent/metastatic disease completed six cycles of TPS as a palliative chemotherapy, whereas 27 of 29 patients with locally advanced disease completed three cycles of TPS as induction chemotherapy. /week), we amended the protocol to include a dose escalation of docetaxel and shortening of treatment cycle and limited the subjects to patients with locally advanced disease. In other words, MTD was evaluated at dose level 5 or 6 to determine the RD of TPS as induction chemotherapy for locally advanced HNC.
At dose level 5, two DLTs were observed, namely one grade 3 infection and one grade 3 hyperbilirubinemia, establishing this as the MTD. The relative dose intensity at this dose level was 0.67 (range 0.40-0.85). In the 12 patients at dose level 6, two DLTs were observed, namely one grade 3 elevation of alanine aminotransferase/aspartate aminotransferase and one grade 3 diarrhea. The relative dose intensity at this dose level was 0.92 (range 0.41-1.0). Based on the results, the RD of this combination was determined as docetaxel 70 mg/m 2 , cisplatin 70 mg/m 2 , and S-1 60 mg/m 2 for 14 days, every 3 weeks.
toxicity
Overall toxic effects during TPS administration are listed in Table 3 . Grade 3 or 4 hematological toxic effects are listed by dose level in Table 4 . At dose level 5, all patients experienced grade 4 neutropenia. Grade 2 or 3 nonhematological toxic effects are listed by dose level in Table 5 . No grade 4 nonhematological toxic effects were observed during any course. Major common grade 3 or 4 toxic effects in patients with locally advanced disease during chemoradiotherapy or proton beam therapy were mucositis (48%), dysphagia (34%), leucopenia (28%), anemia (17%), dermatitis (17%), and neutropenia (14%). Toxicity was as expected and manageable.
treatment outcomes
Efficacy data are listed in Table 6 . All patients enrolled in this study were assessable for response to TPS. There were 6 complete and 22 partial responses, giving an overall response rate of 70% [95% confidence interval (CI) 59.1-80.8], broken down as 4 complete and 18 partial responses in the 29 patients with locally advanced disease, and 2 complete and 4 partial responses in the 11 with recurrent/metastatic disease. One of these latter two complete responders, who had residual disease after completion of radiotherapy for poorly differentiated squamous cell carcinoma of the nasopharynx, achieved a complete response after receiving three cycles of TPS without further treatment and remains alive without evidence of recurrence as of $5 years later. Another patient, who had previous radiotherapy for undifferentiated carcinoma of the nasopharynx and multiple mediastinal lymph node metastases 4 months after receiving lobectomy for lung metastasis, achieved a complete response after completion of six cycles of TPS followed by S-1 alone for 2 years and is alive without evidence of disease progression as of >4 years after treatment. Although no objective response was observed in patients with adenoid cystic carcinoma, eight of nine patients with undifferentiated carcinoma achieved an objective response.
Of the 29 patients with locally advanced disease, 23 (79%; 95% CI, 64% to 93%) experienced complete remission after completion of definitive chemoradiotherapy or proton beam Grade  Grade  Grade  Grade  Grade  2  3  2  3  2  3  2  3  2  3 therapy. Three patients achieved a partial response and the remaining three patients showed progressive disease, including bone metastasis (n = 2). With a median follow-up time of 19 months (range 6-52 months), locoregional recurrence and distant metastasis were observed in nine and four patients, respectively. A total of six patients died due to disease progression. Although the patient population was heterogeneous, the estimated 1-year PFS and OS in all patients were 64% and 85%, respectively. The estimated 1-year PFS in patients with recurrent/metastatic and locally advanced disease were 33% and 74%, respectively.
discussion
The past 5-10 years has seen an increasing trend for the substitution of conventional 5-FU with oral prodrugs of 5-FU, including S-1 and capecitabine, in chemotherapy regimens. Two randomized trials for advanced gastric cancer evaluated the safety and efficacy of S-1 compared with that of 5-FU: in one trial, S-1 showed statistically significant noninferiority to 5-FU (P < 0.001) [12] , while in another trial [13] , S-1 plus cisplatin was statistically noninferior to 5-FU plus cisplatin and had a significantly superior safety profile. These randomized trials have identified S-1 as a valuable substitute for bolus or infusional 5-FU in the treatment of gastric cancer. Three trials of TPS in the treatment of advanced gastric cancer have been reported [14] [15] [16] . Given recognition in Japan that S-1 is a key drug in the treatment of gastric cancer, S-1 dose was fixed (S-1 80 mgÁm 2 /day on days 1-14) in all three trials, whereas dose intensities of docetaxel and cisplatin were markedly lower (docetaxel 10 or 20 mgÁm 2 /week, cisplatin 17.5 or 20 mgÁm 2 /week) than those of the standard TPF regimen (docetaxel 25 mgÁm 2 /week, cisplatin 25 mgÁm 2 /week) for SCCHN [2, 3] . Given the outcomes of the TAX 323 and TAX324 studies [2, 3] , which demonstrated that, in addition to cisplatin, docetaxel is a key drug in the treatment of SCCHN, these TPS regimens would therefore not be appropriate substitutes for TPF in the treatment of SCCHN.
In contrast to the situation for gastric cancer, no randomized trial has compared S-1 with 5-FU for HNC and no previous studies have investigated TPS in the treatment of HNC. The present study is thus the first trial of TPS in the treatment of HNC. Results showed that the incidence of hematological toxic effects was comparable to that in TAX 323 and TAX324, whereas no grade 4 nonhematological toxic effects or treatment-related deaths were seen. At dose level 5 (docetaxel 70 mg/m 2 , cisplatin 70 mg/m 2 , and S-1 80 mg/m 2 , every 3 weeks), two DLTs were observed, establishing this as the MTD. All patients at this level experienced grade 4 neutropenia and the relative dose intensity was 0.67, suggesting that this dose would not be feasible. At dose level 6 (docetaxel 70 mg/m 2 , cisplatin 70 mg/m 2 , and S-1 60 mg/m 2 , every 3 weeks), 2 of 12 patients developed DLTs and the relative dose intensity at this dose level was 0.92, suggesting the feasibility of this dose as the RD of a phase II trial.
The rate of treatment-related death with the most widely accepted standard TPF regimen is 2.3% [2] . This is of concern, given that the goal of treatment for patients with locally advanced SCCHN is cure. Although the docetaxel and cisplatin doses at dose level 6 (docetaxel 70 mg/m 2 , cisplatin 70 mg/m 2 , and S-1 60 mg/m 2 , every 3 weeks) were slightly lower than those with standard TPF, the incidence of febrile neutropenia (33%) was higher than that with standard TPF (5.2%), suggesting that further dose escalation may increase the risk of the treatment-related death. Hence, no further dose escalation was undertaken.
Many patients with locally advanced HNC experience dysphagia due to the primary tumor, and difficulty in swallowing capsules containing S-1 may be problematic. Nutritional support via feeding tube replacement in these patients is indispensable. Our previous pharmacokinetic findings showed that administration of S-1 as a suspension via a feeding tube was interchangeable with oral administration of whole capsules [17] . S-1 can therefore be administered to all HNC patients regardless of difficulty in swallowing capsules.
Although efficacy was not a primary end point of this study, antitumor activity (overall response rate 70%) was highly promising. Moreover, both patients with recurrent/metastatic nasopharyngeal cancer achieved a complete response after treatment, and remain alive and without recurrence at >4 years post-treatment. Although the number of patients was small and nasopharyngeal cancer is more sensitive to chemotherapy than other primary sites of HNC, antitumor activity was noteworthy. Furthermore, toxic effects during definitive therapy were relatively mild compared with those in previous studies of concurrent chemoradiotherapy for locally advanced SCCHN, suggesting that three cycles of TPS would not compromise the delivery of subsequent chemoradiotherapy.
During dose levels 1-4, this study included patients with recurrent/metastatic disease. If TPS had shown feasible and promising efficacy in these patients, this would have been encouraged further investigation to establish a new standard of care in the treatment of recurrent/metastatic SCCHN. Of 11 patients with recurrent/metastatic disease, however, 2 refused further treatment due to fatigue, even though they had achieved a clinical response and experienced no severe toxic effects, and almost all had limited treatment options if they had proved refractory to this combination. We therefore excluded patients with recurrent/metastatic disease from receiving dose levels 5 Annals of Oncology original article and 6. Recently, the addition of cetuximab to platinum-based chemotherapy was shown to significantly prolong OS without exacerbating chemotherapy-associated toxicity or quality of life in patients with recurrent/metastatic SCCHN [18] . The addition of molecular-targeted drugs such as cetuximab to platinum-based chemotherapy would therefore be more feasible and appropriate than that of docetaxel to platinumbased chemotherapy in the treatment of recurrent/metastatic SCCHN. Concern has been expressed over the considerable ethnic differences in the tolerated doses of S-1. These relate to the varying efficiency rates of conversion of tegafur to 5-FU by CYP2A6 of the CYP450 enzyme system, now identified as the principal enzyme responsible for this conversion process [19] [20] [21] [22] . A phase I study of S-1 plus cisplatin in Western patients with advanced gastric carcinoma showed that the S-1 dose tolerated by Western patients is lower than that by Japanese patients but that the area under the curve of 5-FU appears higher in white than Japanese patients in a comparable dose range of S-1 [23] . This is mostly attributed to different polymorphisms in the CYP2A6 gene among Asians and whites. The RD of the present study is likely unsuitable for Western patients, and further study to determine the RD of TPS for these patients is required. Moreover, further study of the present TPS should be done in Asian patients to clarify whether TPS is superior to TPF.
In conclusion, we found that treatment with TPS was well tolerated and feasible in patients with locally advanced HNC. This regimen demonstrated sufficient activity to warrant phase II testing and may be an optimal substitute for TPF in the treatment of locally advanced SCCHN. A randomized trial comparing TPS with TPF in patients with locally advanced SCCHN is warranted.
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